Collaboration and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 30, 2019	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaboration And License Agreements [Line Items]
Stock issued during period, value, new issues			$ 9,530,000	$ 60,836,000
Research and development		$ 7,428,000			$ 5,345,000	$ 19,759,000	$ 10,844,000
Anacor Licensing Agreement
Collaboration And License Agreements [Line Items]
Number of days convenience upon written notice until first regulatory approval.	90 days
Number of days convenience upon written notice thereafter	1 year
Payment of non-refundable upfront payment	$ 2,000,000.0
Research and development						$ 1,000,000.0	$ 300,000
Aggregate maximum payments upon achievement of development milestones	2,000,000.0
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 125,000,000.0
Royalty percentage	50.00%
Number of years, sales royalty required to be paid	15 years
Anacor Licensing Agreement | Series A Redeemable Convertible Preferred Stock
Collaboration And License Agreements [Line Items]
Aggregate granted shares	1,362,499
Fair value of shares per share	$ 2.46
Stock issued during period, value, new issues	$ 3,400,000
Shares granted per share price paid	$ 2.55
Fair value of consideration	$ 5,400,000
Brii Biosciences Agreement
Collaboration And License Agreements [Line Items]
Aggregate maximum payments upon achievement of commercial and sales threshold milestones	$ 150,000,000
Number of years, sales royalty required to be paid	15 years
Upfront payment received	$ 0
Brii Biosciences Agreement | Maximum
Collaboration And License Agreements [Line Items]
Aggregate development and regulatory milestones eligible to receive	$ 15,000,000.0